☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
BT
Novartis's SEG101(crizanlizumab) Receives FDA's Breakthrough Therapy(BT) Designation for Sickle Cell Disease
January 8, 2019
Load more...
Back to Home